Optinose (OPTN) AI Stock Analysis

• Market Cap: $97.22M
• Dividend Yield: N/A
• Average Volume (3M): 86.54K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: 10.58%
• EPS Growth: 34.44%
• Country: US
• Employees: 127
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -1.92
• Shares Outstanding: 41,436,000
• 10 Day Avg. Volume: 118,331
• 30 Day Avg. Volume: 86,543
• PEG Ratio: <0.01
• Price to Book (P/B): -1.84
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.32
• Enterprise Value/Market Cap: 1.57
• Enterprise Value/Revenue: 0.49
• Enterprise Value/Gross Profit: 2.06
• Enterprise Value/Ebitda: -4.76
• 1Y Price Target: $9.00
• Price Target Upside: -6.25% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

• Rating: 50 Neutral
• Price Target: $9.50 ▼(-1.04%Downside)

Optinose's overall stock score reflects significant financial challenges despite recent positive technical trends and a promising corporate event. The company's high leverage, negative equity, and ongoing unprofitability are critical risks. The merger with Paratek may offer strategic opportunities, but a strategic turnaround is necessary to improve financial stability and stock performance.

Positive Factors

Acquisition Impact

The acquisition of OptiNose by Paratek Pharmaceuticals reflects a 50% premium to OptiNose's previous closing trading price, indicating a positive financial outlook.

Market Expansion

The approval of an sNDA expands the addressable market by 3x and alleviates payer challenges, significantly increasing the total addressable market compared to XHANCE’s original opportunity.

Revenue Growth

The company reported a significant revenue growth of 24% year-over-year, exceeding consensus expectations.

Negative Factors

Rating Downgrade

The rating for OptiNose has been changed to Neutral and the price target reduced, reflecting adjustments in light of the announced acquisition.

Share Price Movement

OPTN shares have drifted significantly since the 3Q24 report, perhaps contributing to the price the Company was able to command from Paratek.

Stock Delisting

OptiNose’s common stock is to be delisted from NASDAQ with the expected acquisition closing.

Optinose Business Overview & Revenue Model

Company Description

Optinose (OPTN) is a specialty pharmaceutical company focused on developing and commercializing innovative products for patients treated by ear, nose, and throat (ENT) and allergy specialists. The company's core product, XHANCE, is a nasal spray designed to treat chronic rhinosinusitis with nasal polyps in adults. Optinose operates primarily within the healthcare and pharmaceutical sectors, leveraging its proprietary Exhalation Delivery System to provide effective treatments for ENT conditions.

How the Company Makes Money

Optinose makes money primarily through the sale of its flagship product, XHANCE, which is a prescription nasal spray. The company's revenue is generated from direct sales to specialty pharmacies and distributors, who then supply the product to healthcare providers and patients. Optinose's revenue model relies on physician prescriptions and patient demand for XHANCE, driven by its effectiveness in treating chronic rhinosinusitis with nasal polyps. Additionally, Optinose engages in partnerships and collaborations with other healthcare entities to expand its market reach and increase product adoption, though specific details on significant partnerships are not available.

Optinose Financial Statement Overview

Summary

Optinose faces significant financial challenges, characterized by persistent losses, high leverage, and negative equity. Despite some revenue growth, the company struggles to achieve profitability and positive cash flow. The financial health of the company is precarious, necessitating a strategic turnaround to stabilize and improve its financial position.

Income Statement

Optinose has shown some improvement in revenue, with a growth rate of 10.2% from 2023 to 2024. However, profitability remains a concern as indicated by the negative net profit margin of -27.5% and negative EBIT margin of -20.9% in 2024. The company is struggling to convert increased revenue into positive earnings, which suggests ongoing challenges in cost management or market conditions.

Balance Sheet

The balance sheet reveals significant financial instability, with a negative stockholders' equity of -$40.36 million in 2024, indicating insolvency. The debt-to-equity ratio cannot be calculated meaningfully due to negative equity, but high total debt of $126.48 million poses a risk. The company is heavily leveraged, which could impair its ability to sustain operations without external financing.

Cash Flow

Optinose's cash flow situation is challenging, with negative free cash flow of -$44.75 million in 2024. The operating cash flow to net income ratio is not favorable, suggesting difficulties in generating cash from operations. The reliance on financing activities to sustain cash levels highlights potential liquidity issues if external financing dries up.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
81.86M	78.23M	70.99M	76.28M	74.65M	49.12M
	Gross Profit
74.11M	71.00M	62.35M	67.01M	65.50M	41.60M
	EBIT
-15.84M	-16.32M	-22.75M	-55.90M	-66.45M	-87.22M
	EBITDA
239.00K	-1.20M	-15.55M	-57.46M	-65.68M	-85.32M
	Net Income Common Stockholders
-29.89M	-21.54M	-35.48M	-76.39M	-81.65M	-98.33M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
73.68M	84.48M	73.68M	94.24M	110.50M	144.16M
	Total Assets
107.73M	128.78M	107.73M	144.22M	166.07M	188.81M
	Total Debt
131.75M	128.96M	131.75M	131.17M	130.70M	125.20M
	Net Debt
58.06M	44.48M	58.06M	36.93M	20.20M	-18.95M
	Total Liabilities
194.34M	169.15M	194.34M	200.84M	187.84M	182.03M
	Stockholders Equity
-86.61M	-40.36M	-86.61M	-56.62M	-21.77M	6.79M
Cash Flow		Free Cash Flow
-22.70M	-44.75M	-20.86M	-67.71M	-77.10M	-86.75M
	Operating Cash Flow
-22.86M	-44.89M	-20.53M	-67.65M	-76.94M	-86.21M
	Investing Cash Flow
-50.00K	-72.00K	-328.00K	-63.00K	-62.00K	-546.00K
	Financing Cash Flow
55.55M	55.55M	300.00K	51.44M	43.32M	83.81M

Optinose Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPTN, the sentiment is Positive. The current price of 9.6 is above the 20-day moving average (MA) of 9.47, above the 50-day MA of 9.00, and above the 200-day MA of 9.03, indicating a bullish trend. The MACD of 0.20 indicates Positive momentum. The RSI at 72.36 is Negative, neither overbought nor oversold. The STOCH value of 57.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OPTN.

Optinose Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.37B	3.35	-45.10%	2.79%	16.77%	-0.01%
OPTN	50 Neutral	$97.22M	―	75.79%	―	10.58%	34.44%
GALT	35 Underperform	$84.81M	―	48.74%	―	―	-1.60%
BDTX	33 Underperform	$139.88M	39.87	4.14%	―	―	33.97%
VOR	33 Underperform	$28.68M	―	-125.43%	―	―	2.98%

Optinose Corporate Events

Optinose Acquired by Paratek Pharmaceuticals for $330 Million

Optinose, a company involved in the pharmaceutical industry, has undergone significant changes following a merger agreement. On May 21, 2025, Optinose was acquired by Paratek Pharmaceuticals, resulting in the termination of Optinose’s obligations under its Note Purchase Agreement and the delisting of its common stock from Nasdaq. The merger, valued at approximately $330 million, includes contingent value rights for Optinose shareholders based on future sales milestones of their product XHANCE. This acquisition expands Paratek’s portfolio, which now includes Optinose’s XHANCE alongside Paratek’s antibiotic NUZYRA, positioning Paratek as a multi-product specialty therapeutics company.

The most recent analyst rating on (OPTN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Optinose stock, see the OPTN Stock Forecast page.

Optinose Stockholders Approve Merger with Paratek

On May 16, 2025, OptiNose, Inc. held a special meeting of stockholders where key proposals were voted on. The company, involved in a merger with Paratek Pharmaceuticals, Inc., had 10,127,381 shares eligible to vote, with a quorum of 8,406,605 shares represented. The stockholders approved the Merger Agreement Proposal with Paratek, receiving a 77.96% affirmative vote. Additionally, the Advisory Compensation Proposal was approved with an 81.65% affirmative vote. The Adjournment Proposal was deemed unnecessary due to sufficient votes for the merger.

The most recent analyst rating on (OPTN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Optinose stock, see the OPTN Stock Forecast page.